Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Doctor-Tailored stent graft aims to tame deadly aortic aneurysms

NCT ID NCT02989948

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study tests a stent graft that doctors modify to fit each patient's unique aneurysm in the chest and abdomen. The goal is to see if this less invasive approach is as safe and effective as traditional open surgery. About 80 people aged 50 and older with large aneurysms will take part. Success is measured by survival, complications, and whether the aneurysm is sealed off at one year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
physician-modified aortic stent graft
What this could lead to
If successful, this could offer a less invasive treatment option for complex aortic aneurysms, potentially reducing recovery time and complications compared to open surgery.
What could go wrong
This is a single-arm study with only 80 participants, so results may not apply to all patients. The graft is modified by the physician, which could lead to variability in outcomes, and there are risks like rupture or device failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2020

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 95 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

MAIN ARM - Inclusion Criteria: 1. Must be a man or woman 50 years of age or older by the date of informed consent. 2. Must have a thoracoabdominal aortic aneurysm of any Crawford classification (extent I-V) that extends no more proximal than the left subclavian artery. 3. Must have an aneurysm size that meets standard indications for surgical repair (6.0 cm in maximum diameter in the descending thoracic aorta, or 5.5 cm in maximum diameter in the abdominal aorta). 4. Must be considered, in the judgment of the S-I, to be a high risk candidate for open surgical repair. 5. Must not be a candidate for repair under the Instructions for Use of a commercially available, FDA-approved endovascular graft. 6. Must be able to provide informed consent. 7. Must be able to comply with the five year study assessment schedule of events. 8. Must have a non-aneurysm-related life expectancy, in the judgment of the S-I, of greater than 2 years. MAIN ARM - Exclusion Criteria: 1. Aneurysm due to acute or chronic dissection, intramural hematoma, penetrating aortic ulceration, pseudoaneurysm, mycotic aneurysm, or traumatic transection. 2. Ruptured or acutely symptomatic aortic aneurysm. 3. Known connective tissue disorder. 4. Imaging demonstrating any of the following: * Lack of 20 mm non-aneurysmal proximal seal zone (zone 3, or zone 2 with a carotid-subclavian bypass or transposition). * Lack of 15 mm non-aneurysmal distal seal zone(s) (aortic, common iliac, or external iliac). * Branch vessel target (renal, superior mesenteric, or celiac) \< 5 mm or \> 10 mm in average diameter. * Untreated left subclavian artery stenosis or occlusion. * Untreated unilateral or bilateral hypogastric artery occlusion. * Signs that the inferior mesenteric artery is indispensable. * Have branching, duplication, aneurysm, or untreatable stenosis of the celiac, superior mesenteric artery, or renal arteries that would preclude implantation of the investigational devices. 5. Known sensitivities or allergies to stainless steel, PTFE, polyester, polypropylene, nitinol, or gold. 6. History of anaphylaxis to contrast, with inability to prophylax appropriately. 7. Have uncorrectable coagulopathy. 8. Have unstable angina. 9. Have a body habitus that would inhibit X-ray visualization of the aorta. 10. Have a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned ≤30 days of the endovascular repair. 11. Known to be participating in any other clinical study which may affect performance of this device. 12. Known, visible, or suspected pregnancy, confirmed with a Urine Pregnancy Test (UPT) 13. Contraindication to oral antiplatelet therapy. 14. Prisoners or those on alternative sentencing. 15. Known systemic infection with potential for endovascular graft infection. 16. Anticipated need for MRI scanning within 3 months of insertion of investigational product. 17. Other conditions or comorbidities that, in the opinion of the S-I, would exclude the patient. EXPANDED ACCESS ARM - Inclusion Criteria 1. Must be a man or woman 50 years of age or older by the date of informed consent 2. Must have a thoracic, thoracoabdominal, or abdominal aortic aneurysm that necessitates coverage of one or more visceral vessels (celiac, superior mesenteric, or renals) for establishment of proximal and/or distal seal. 3. Must have an aneurysm size that meets standard size indications for surgical repair (6.0 cm in maximum diameter in the descending thoracic aorta, or 5.5 cm in maximum diameter in the abdominal aorta); or, in the judgment of the S-I, has aneurysm characteristics that portend a high risk of near-term rupture 4. Must be considered, in the judgement of the S-I, to be a high risk candidate for open surgical repair 5. Must not be a candidate for repair under the Instructions for Use of a commercially available, FDA-approved endovascular graft 6. Patient must be able to provide informed consent 7. Must be able to comply with the five year study assessment schedule of events 8. Must have a non-aneurysm-related life expectancy, in the judgement of the S-I, of greater than 2 years EXPANDED ACCESS ARM - Exclusion Criteria 1. Known or suspected mycotic aneurysm 2. Ruptured aneurysm with hemodynamic instability 3. Known connective tissue disorder 4. Imaging demonstrating any of the following: * Lack of 20 mm non-aneurysmal proximal seal zone (in either native aorta, elephant trunk graft, or aortic arch endograft) * Lack of 15 mm non-aneurysmal distal seal zone(s) (in either native aortoiliac vessels, prosthetic aortoiliac grafts, or aortoiliac endografts) * Branch vessel target (renal, superior mesenteric, or celiac) \> 10 mm in average diameter 5. Known sensitivities or allergies to stainless steel, PTFE, polyester, polypropylene, nitinol, or gold 6. History of anaphylaxis to contrast, with inability to prophylax appropriately. 7. Have uncorrectable coagulopathy 8. Have a body habitus that would inhibit X-ray visualization of the aorta 9. Have a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned ≤ 30 days of the endovascular repair 10. Known to be participating in any other clinical study which may affect performance of this device 11. Known, visible, or suspected pregnancy, confirmed with a Urine Pregnancy Test (UPT) 12. Contraindication to oral antiplatelet therapy 13. Prisoners or those on alternative sentencing 14. Known systemic infection with potential for endovascular graft infection 15. Anticipated need for MRI scanning within 3 months of insertion of investigational product 16. Other conditions or comorbidities that, in the opinion of the S-I, would exclude the patient

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aortic aneurysm, thoracoabdominal are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aortic aneurysm Aortic Aneurysm, Thoracoabdominal

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dartmouth-Hitchcock Medical Center

    ACTIVE_NOT_RECRUITING

    Lebanon, New Hampshire, 03766, United States

  • Yale New Haven Hospital

    RECRUITING

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.